{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T22:28:25Z","timestamp":1770935305220,"version":"3.50.1"},"reference-count":129,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2001,8]]},"DOI":"10.1517\/13543784.10.8.1487","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T15:40:34Z","timestamp":1115221234000},"page":"1487-1500","source":"Crossref","is-referenced-by-count":1,"title":["New therapies and vaccines for meningococcal disease"],"prefix":"10.1517","volume":"10","author":[{"given":"Enitan D","family":"Carrol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alistair PJ","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C Anthony","family":"Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2005,2,24]]},"reference":[{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/13.1.22"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91112-8"},{"key":"e_1_2_1_7_1","first-page":"169","article-title":"RODAHLK, GEDDE-DAHL TW: Factors preceding the onset of meningococcal disease, with special emphasis on passive smoking, symptoms of ill health","volume":"6","author":"HANEBERG B","year":"1983","unstructured":"HANEBERG B, TONJUM T, RODAHLK, GEDDE-DAHL TW: Factors preceding the onset of meningococcal disease, with special emphasis on passive smoking, symptoms of ill health. NIPH Ann. (1983) 6:169\u2013173.","journal-title":"NIPH Ann."},{"key":"e_1_2_1_8_1","unstructured":"POOLMAN JT LEY PAVD TOMMASSEN J: Surface structures and Secreted Products of Meningococci. In: Merringococcal Disease. Cartwright K (Ed.) Jon Wiley and Sons Ltd Chichester England (1995):21\u201334."},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.2.195"},{"key":"e_1_2_1_10_1","unstructured":"\u2022\u2022Important paper showing correlation between endotoxin levels and disease severity."},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/160.1.58"},{"key":"e_1_2_1_12_1","unstructured":"\u2022\u2022Important paper showing correlation between endotoxin levels and disease severity."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/166.3.650"},{"key":"e_1_2_1_14_1","first-page":"200","article-title":"Plasma lipopolysaccharide (LPS)-binding protein","volume":"149","author":"MATHISON JC","year":"1992","unstructured":"MATHISON JC, TOBIAS PS, WOLFSON E, ULEVITCH RJ: Plasma lipopolysaccharide (LPS)-binding protein. A key component in macrophage recognition of gram-negative LPS. I Immune]. (1992) 149:200\u2013206.","journal-title":"A key component in macrophage recognition of gram-negative LPS. I Immune]."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110945"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.163.3.740"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198905043201802"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01720912"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114265"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.10.4244-4249.1994"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4008.bloodjournal84124008"},{"key":"e_1_2_1_22_1","doi-asserted-by":"crossref","unstructured":"HAZELZET JA KORNELISSE RE VAN DER POUW KRAAN TC et al.: Interleukin 12 levels during the initial phase of septic shock with purpura in children: relation to severity of disease. Cytolone (1997) 9:711\u2013716.","DOI":"10.1006\/cyto.1997.0215"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.75.5.453"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.2.433"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91728-4"},{"key":"e_1_2_1_26_1","unstructured":"\u2022\u2022Important publication demonstrating association between high TNF levels and poor outcome."},{"key":"e_1_2_1_27_1","doi-asserted-by":"crossref","unstructured":"WAAGE A BRANDTZAEG P HALSTENSEN A KIERULF P ESPEVIK T: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6 interleukin 1 and fatal outcome. J. Exp. Med. (1989) 169:333\u2013338.","DOI":"10.1084\/jem.169.1.333"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-8-199310150-00001"},{"key":"e_1_2_1_29_1","unstructured":"LEVIN M GALASSINI R DE MUNTER C AND THE MENINGOCOCCAL STUDY GROUP: Improved survival in children admitted to intensive care with meningococcal disease. Proceedings of the 2nd Annual Meeting of the Royal College of Paediatrics and Child Health. York England (1998)."},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-199901040-00003"},{"key":"e_1_2_1_31_1","first-page":"1225","article-title":"Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli N Engl","volume":"307","author":"ZIEGLER EJ","year":"1982","unstructured":"ZIEGLER EJ, MCCUTCHAN JA, FIERER J et al:Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli N Engl. J. Med. (1982) 307:1225\u20131230.","journal-title":"J. Med."},{"key":"e_1_2_1_32_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(85)90176-X","article-title":"Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid","volume":"2","author":"BAUMGARTNER JD","year":"1985","unstructured":"BAUMGARTNER JD, GLAUSER MP, MCCUTCHAN JA et al.: Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet (1985) 2:59\u201363.","journal-title":"Lancet"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.4.695"},{"key":"e_1_2_1_34_1","doi-asserted-by":"crossref","unstructured":"ZIEGLER EJ FISHER CJ JR SPRUNGCL et al.: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized double-blind placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl. J. Med. (1991) 324:429\u2013436.","DOI":"10.1056\/NEJM199102143240701"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-1-199407010-00001"},{"key":"e_1_2_1_36_1","first-page":"770","article-title":"Randomized, placebo-controlled trial of HA-1A, a monoclonal antibody to endotoxin, in children with meningococcal septic shock","volume":"28","author":"DERX B","year":"1999","unstructured":"DERX B, WITTES J, MCCLOSKEY R: Randomized, placebo-controlled trial of HA-1A, a monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial study Group. Chu Infect Dis (1999) 28:770\u2013777.","journal-title":"European Pediatric Meningococcal Septic Shock Trial study Group. Chu Infect Dis"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115930"},{"key":"e_1_2_1_38_1","unstructured":"\u2022\u2022One of the earliest publicationsdemonstrating bactericidal effects of BPI."},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.11.4754-4761.1992"},{"key":"e_1_2_1_40_1","unstructured":"LAMBERT L WONG P HOPPE P: Recombinant bactericidal\/permeability-increasing (rBPI) protein kills both gram-positive and gram-negative bacteria. Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Orlando Florida (1994)."},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06468-4"},{"key":"e_1_2_1_42_1","doi-asserted-by":"crossref","unstructured":"LEVIN M QUINT PA GOLDSTEIN B etal.: Recombinant bactericidal\/ permeability-increasing protein (rBPI 21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet (2000) 356:961\u2013967.","DOI":"10.1016\/S0140-6736(00)02712-4"},{"key":"e_1_2_1_43_1","unstructured":"\u2022\u2022Important publication reporting results ofthe first large multicentre trial of BPi in severe meningococcal sepsis."},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.16.10689"},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.20.6120"},{"key":"e_1_2_1_46_1","doi-asserted-by":"crossref","unstructured":"BUNNELL E LYNN M HABET K et at.: A lipid A analog E5531 blocks the endotoxin response in human volunteers with experimental endotoxemia. Crk Care Med. (2000) 28:2713\u20132720.","DOI":"10.1097\/00003246-200008000-00005"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0310057X9602400212"},{"key":"e_1_2_1_48_1","unstructured":"\u2022\u2022Excellent review of pathophysiology andmanagement of acute meningococcaemia."},{"key":"e_1_2_1_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)83649-3"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.2.357.357"},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/4.2.221"},{"key":"e_1_2_1_52_1","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.4049\/jimmunol.153.8.3664","article-title":"Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester","volume":"153","author":"GREY ST","year":"1994","unstructured":"GREY ST, TSUCHIDA A, HAU H, ORTHNER CL, SALEM HH, HANCOCK WW: Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester.j ImmurroL (1994) 153:3664\u20133672.","journal-title":"j ImmurroL"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01709832"},{"key":"e_1_2_1_54_1","unstructured":"\u2022Publication describing relationship between protein C and S concentrations and outcome."},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(95)70369-1"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06356-3"},{"key":"e_1_2_1_57_1","unstructured":"FAUST SN HEYDERMAN RS et al.: Molecular mechanisms of thrombosis in meningococcal septicaemia: the role of the protein C pathway in vivo. Proceedings of the 5th world congress on Trauma Shock Inflammation and Sepsis. Munich 2000. Shock (2000) 13:29."},{"key":"e_1_2_1_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103083441001"},{"key":"e_1_2_1_59_1","first-page":"1205","article-title":"Attenuation of the Schwartzman reaction in rabbits by activated protein C","volume":"65","author":"PILCHER L","year":"1991","unstructured":"PILCHER L, HRUBY E, SCHWARZ HP: Attenuation of the Schwartzman reaction in rabbits by activated protein C. Thromb. Haemostat. (1991) 65:1205.","journal-title":"Thromb. Haemostat."},{"key":"e_1_2_1_60_1","first-page":"121","volume":"16","author":"FOURRIER F","year":"1990","unstructured":"FOURRIER F, LESTAVEL P, CHOPIN C eta].: Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med. (1990) 16:121\u2013124.","journal-title":"CHOPIN C eta].: Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med."},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.104.3.882"},{"key":"e_1_2_1_62_1","doi-asserted-by":"crossref","unstructured":"FOURRIER F JOURDAIN M TOURNOYS A: Clinical trial results with antithrombin III in sepsis. Grit. Care Med. (2000)28(9 suppl):538\u2013543.","DOI":"10.1097\/00003246-200009001-00009"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199410000-00004"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(93)90209-4"},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(92)90071-H"},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199109000-00017"},{"key":"e_1_2_1_67_1","first-page":"959","volume":"79","author":"ATTANASIO M","year":"1998","unstructured":"ATTANASIO M, GORI AM, GIUSTI Bet al.: Cytokine gene expression in human LPS- and IFNgamma-stimulated mononuclear cells is inhibited by heparin. Thromb. Haemost. (1998) 79:959\u2013962.","journal-title":"GIUSTI Bet al.: Cytokine gene expression in human LPS- and IFNgamma-stimulated mononuclear cells is inhibited by heparin. Thromb. Haemost."},{"key":"e_1_2_1_68_1","first-page":"187","article-title":"RIORDAN FAI, HART CA: A retrospective review of the use of prostacyclin in severe meningococcal sepsis","volume":"8","author":"BAINES PB","year":"1996","unstructured":"BAINES, PB, THOMSON APJ, SILLS JA, RIORDAN FAI, HART CA: A retrospective review of the use of prostacyclin in severe meningococcal sepsis. Pediatr. Rev. Commun. (1996) 8:187.","journal-title":"Pediatr. Rev. Commun."},{"key":"e_1_2_1_69_1","first-page":"2","article-title":"The therapeuticvalue of vasodilator prostaglandins in multiple organ failure associated with sepsis","volume":"15","author":"BIHARI DJ","year":"1988","unstructured":"BIHARI DJ, TINKER J: The therapeuticvalue of vasodilator prostaglandins in multiple organ failure associated with sepsis. Intensive Cafe Med. (1988) 15: 2\u20137.","journal-title":"Intensive Cafe Med."},{"key":"e_1_2_1_70_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.66.11.1296"},{"key":"e_1_2_1_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02623.x"},{"key":"e_1_2_1_72_1","first-page":"932","volume":"76","author":"HAZELZET JA","year":"1996","unstructured":"HAZELZET JA, RISSEEUW-APPEL IM, KORNELISSE RF etal.: Age-related differences in outcome and severity of DIC in children with septic shock and purpura. Thromb. Haemost. (1996) 76:932\u2013938.","journal-title":"KORNELISSE RF etal.: Age-related differences in outcome and severity of DIC in children with septic shock and purpura. Thromb. Haemost."},{"key":"e_1_2_1_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.5.1148"},{"key":"e_1_2_1_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199805000-00039"},{"key":"e_1_2_1_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311253292204"},{"key":"e_1_2_1_76_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199706000-00028"},{"key":"e_1_2_1_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199805000-00041"},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199805000-00040"},{"key":"e_1_2_1_79_1","unstructured":"ZENZ W et al.: Use of tissue plaminogen activator (t-PA) in children with fulminant meningococcaemia- a retrospective multicenter study. Proceedings of the European Soden of Intensive Care Medicare. Rome Italy (2000)"},{"key":"e_1_2_1_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199507000-00021"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199804000-00010"},{"key":"e_1_2_1_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199904000-00025"},{"key":"e_1_2_1_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/15.3.431"},{"key":"e_1_2_1_84_1","first-page":"757","article-title":"Plasmapheresis in the treatment of primary septic shock in humans","volume":"25","author":"GARDLUND B","year":"1993","unstructured":"GARDLUND B, SJOLIN J, NILSSON A et al.: Plasmapheresis in the treatment of primary septic shock in humans. Land. Infect. Dis. (1993) 25:757\u2013761.","journal-title":"Land. Infect. Dis."},{"key":"e_1_2_1_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/15.3.424"},{"key":"e_1_2_1_86_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199404000-00038"},{"key":"e_1_2_1_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199910000-00003"},{"key":"e_1_2_1_88_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199304000-00011"},{"key":"e_1_2_1_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01706203"},{"key":"e_1_2_1_90_1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1542\/peds.93.5.726","article-title":"Extracorporeal membrane oxygenation for refractory septic shock in children","volume":"93","author":"BECA J","year":"1994","unstructured":"BECA J, BUTT W: Extracorporeal membrane oxygenation for refractory septic shock in children. Pediatrics (1994) 93:726\u2013729.","journal-title":"Pediatrics"},{"key":"e_1_2_1_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90388-8"},{"key":"e_1_2_1_92_1","first-page":"466","volume":"349","author":"GOLDMAN AP KERR SJ,","year":"1997","unstructured":"GOLDMAN AP KERR SJ, BUTT W et al.: Extracorporeal support for intractable cardiorespiratory failure due to meningococcal disease. Lancet (1997) 349:466\u2013469.","journal-title":"BUTT W et al.: Extracorporeal support for intractable cardiorespiratory failure due to meningococcal disease. Lancet"},{"key":"e_1_2_1_93_1","doi-asserted-by":"crossref","unstructured":"'MACEY KJ FONG Y HESSE DG etal.: Anti-cachectin\/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1987) 330:662\u2013664.","DOI":"10.1038\/330662a0"},{"key":"e_1_2_1_94_1","first-page":"279","article-title":"Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha)","volume":"30","author":"HINSHAW LB","year":"1990","unstructured":"HINSHAW LB, TEKAMP-OLSON P, CHANG AC et al.: Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ. Shock (1990) 30:279\u2013292.","journal-title":"Circ. Shock"},{"key":"e_1_2_1_95_1","first-page":"934","volume":"273","author":"ABRAHAM E","year":"1995","unstructured":"ABRAHAM E, WUNDERINK R, SILVERMAN H etal.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA (1995) 273:934\u2013941.","journal-title":"SILVERMAN H etal.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA"},{"key":"e_1_2_1_96_1","unstructured":"\u2022Publication describing the results of one of the first large trials of anti-TNF therapy."},{"key":"e_1_2_1_97_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199609000-00002"},{"key":"e_1_2_1_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)60602-2"},{"key":"e_1_2_1_99_1","first-page":"1650","volume":"26","author":"CLARK MA","year":"1998","unstructured":"CLARK MA, PLANK LD, CONNOLLY AB etal.: Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis: a randomized, clinical trial. Grit. Care Med. (1998) 26:1650\u20131659.","journal-title":"CONNOLLY AB etal.: Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis: a randomized, clinical trial. Grit. Care Med."},{"key":"e_1_2_1_100_1","first-page":"1697","article-title":"Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein","volume":"334","author":"FISHER CJ JR","year":"1996","unstructured":"FISHER CJ, JR, AGOSTI JM, OPAL SM et al: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl. J. Med. (1996) 334:1697\u20131702.","journal-title":"The Soluble TNF Receptor Sepsis Study Group. N Engl. J. Med."},{"key":"e_1_2_1_101_1","doi-asserted-by":"crossref","unstructured":"ABRAHAM E GLAUSER MP BUTLER T etal.: p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45\u20132081 Study Group. JAMA (1997) 277:1531\u20131538.","DOI":"10.1001\/jama.1997.03540430043031"},{"key":"e_1_2_1_102_1","doi-asserted-by":"crossref","unstructured":"FISHER CJ JR DHAINAUT JF OPALSM etal.: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized double-blind placebo-controlled trial. Phase III rhIL-lra Sepsis Syndrome Study Group. JAMA (1994) 271:1836\u20131843.","DOI":"10.1001\/jama.1994.03510470040032"},{"key":"e_1_2_1_103_1","unstructured":"PREAS HL 2ND REDA D TROPEA M etal.: Effects of recombinant soluble Type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood (1996) 88:2465\u20132472."},{"key":"e_1_2_1_104_1","doi-asserted-by":"crossref","unstructured":"OPAL SM FISHER CJ JR DHAINAUT JF et al.: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a Phase III randomized double-blind placebo-controlled multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Grit. Care Med. (1997) 25:115\u2013124.","DOI":"10.1097\/00003246-199707000-00010"},{"key":"e_1_2_1_105_1","doi-asserted-by":"publisher","DOI":"10.1086\/315680"},{"key":"e_1_2_1_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92405-8"},{"key":"e_1_2_1_107_1","first-page":"H176","article-title":"POOLE-WILSON PA, WILLIAMS TJ, HARDING SE: Nitric oxide attenuates cardiac myocyte contraction","volume":"265","author":"BRADY AJ","year":"1993","unstructured":"BRADY AJ, WARREN JB, POOLE-WILSON PA, WILLIAMS TJ, HARDING SE: Nitric oxide attenuates cardiac myocyte contraction. Am.j Physiol (1993) 265:H176\u201382.","journal-title":"Am.j Physiol"},{"key":"e_1_2_1_108_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199906000-00050"},{"key":"e_1_2_1_109_1","unstructured":"\u2022Important publication demonstrating relationship between severity of disease and NO production."},{"key":"e_1_2_1_110_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.15.1184.34587"},{"key":"e_1_2_1_111_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200008000-00035"},{"key":"e_1_2_1_112_1","doi-asserted-by":"crossref","unstructured":"PRIVALLE C TALARICO T KENG T DEANGELO J: Pyridoxalated hemoglobin polyoxyethylene: a nitric oxide scavenger with antioxidant activity for the treatment of nitric oxide-induced shock. Free Radic Biol. Med. (2000) 28:1507-1517. ma GOLD R LEPOW ML GOLDSCHNEIDER I DRAPER TL GOTSCHLICH EC: Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J. an. Invest. (1975) 56:1536\u20131547.","DOI":"10.1016\/S0891-5849(00)00260-4"},{"key":"e_1_2_1_113_1","first-page":"200","article-title":"'IVVUMASI PA, KUMAH S et al","volume":"175","author":"LEACH A","year":"1997","unstructured":"LEACH A, 'IVVUMASI PA, KUMAH S et al.: Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide- protein conjugate vaccine. J. Infect. Dis. (1997) 175:200\u2013204.","journal-title":"Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide- protein conjugate vaccine. J. Infect. Dis."},{"issue":"261","key":"e_1_2_1_114_1","first-page":"264","article-title":"Vaccination programme for group C meningococcal infection is launched","volume":"9","author":"CDSC","year":"1999","unstructured":"CDSC: Vaccination programme for group C meningococcal infection is launched. Commun. Dis. Rep. CDR Wkly (1999) 9:261,264.","journal-title":"Commun. Dis. Rep. CDR Wkly"},{"key":"e_1_2_1_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03594-7"},{"key":"e_1_2_1_116_1","first-page":"1569","volume":"179","author":"RICHMOND E BORROW R,","year":"1999","unstructured":"RICHMOND E BORROW R, MILLER E et al.: Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis. (1999) 179:1569\u20131572.","journal-title":"MILLER E et al.: Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis."},{"key":"e_1_2_1_117_1","unstructured":"\u2022\u2022Key publication demonstrating efficacy ofmeningococcal C conjugate vaccine in infancy."},{"key":"e_1_2_1_118_1","doi-asserted-by":"crossref","unstructured":"FAIRLEY CK BEGG N BORROW R FOX AJ JONES DM CARTWRIGHT K: Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. (1996) 174:1360-1363. los. 'IVVUMASI PA JR KUMAH S LEACH A et al.: A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J. Infect. Dis. (1995) 171:632\u2013638.","DOI":"10.1093\/infdis\/174.6.1360"},{"key":"e_1_2_1_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(91)90338-Y"},{"key":"e_1_2_1_120_1","doi-asserted-by":"crossref","unstructured":"MAKELA PH: Serum antibodies and bacterial meningitis. Trans. R. Sac. Trap. Med. Hyg. (1991) 85:19-22. los. DE MORAES JC PERKINS BA CAMARGO MC et al: Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo Brazil. Lancet (1992) 340:1074\u20131078.","DOI":"10.1016\/0140-6736(92)93086-3"},{"key":"e_1_2_1_121_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.16.1520"},{"key":"e_1_2_1_122_1","doi-asserted-by":"crossref","unstructured":"CARTWRIGHT K MORRIS R RUMKE H etal.: Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine (1999) 17:2612\u20132619.","DOI":"10.1016\/S0264-410X(99)00044-4"},{"key":"e_1_2_1_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00177-2"},{"key":"e_1_2_1_124_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.168.2.507"},{"key":"e_1_2_1_125_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1065"},{"key":"e_1_2_1_126_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1992.tb01458.x"},{"key":"e_1_2_1_127_1","doi-asserted-by":"crossref","unstructured":"AL'ALDEEN AA CARTWRIGHT KA: Neisseria meningitidis vaccines and vaccine candidates. j Infect. (1996) 33:153\u2013157.","DOI":"10.1016\/S0163-4453(96)92081-2"},{"key":"e_1_2_1_128_1","doi-asserted-by":"publisher","DOI":"10.1139\/m89-063"},{"key":"e_1_2_1_129_1","first-page":"751","article-title":"Localization of the meningococcal receptors for human transferrin","volume":"61","author":"ALA'ALDEEN DA","year":"1993","unstructured":"ALA'ALDEEN DA, POWELL NB, WALL RA, BORRIELLO SP: Localization of the meningococcal receptors for human transferrin. Infect. bran= (1993) 61:751\u2013759.","journal-title":"Infect. bran="},{"key":"e_1_2_2_2_1","unstructured":"OPHIDIAN PHARM INC.: U55545721 (1996). zoz. XOMA CORP.: U55952302 (1996)."},{"key":"e_1_2_2_3_1","article-title":"CO","volume":"6008199","author":"ELI LILLY &","year":"1999","unstructured":"ELI LILLY & CO.: US6008199 (1999).","journal-title":"US"},{"key":"e_1_2_2_4_1","unstructured":"BOEHRINGER MANNHEIM GMBH: U55723122 (1998). zos. BASF AS: U55231024 (1993). zos. FONDDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR: W09933989 (1999)."},{"key":"e_1_2_2_5_1","unstructured":"SOCIETE DE CONSEILS RECHERCHES ET D'APPLICATIONSSCIENTIFIQUES: U555972940 (1999). zos. CHIRON CORP.: W09961053 (1999). zos. MICROBIOLOGICAL RES AUTHORITY CAMR: W00025811 (2000)."}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.10.8.1487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T21:52:43Z","timestamp":1770933163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.10.8.1487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":129,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["10.1517\/13543784.10.8.1487"],"URL":"https:\/\/doi.org\/10.1517\/13543784.10.8.1487","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}